Biomea Fusion (BMEA) Competitors $8.88 -0.03 (-0.34%) (As of 11/6/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BMEA vs. EPZM, CHMA, ABOS, PRTK, OVID, XNCR, RCUS, NTLA, EVO, and ARDXShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Epizyme (EPZM), Chiasma (CHMA), Acumen Pharmaceuticals (ABOS), Paratek Pharmaceuticals (PRTK), Ovid Therapeutics (OVID), Xencor (XNCR), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Evotec (EVO), and Ardelyx (ARDX). These companies are all part of the "medical" sector. Biomea Fusion vs. Epizyme Chiasma Acumen Pharmaceuticals Paratek Pharmaceuticals Ovid Therapeutics Xencor Arcus Biosciences Intellia Therapeutics Evotec Ardelyx Epizyme (NASDAQ:EPZM) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Which has preferable valuation & earnings, EPZM or BMEA? Biomea Fusion has lower revenue, but higher earnings than Epizyme. Biomea Fusion is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEpizyme$37.43M6.61-$251.12M-$1.72-0.85Biomea FusionN/AN/A-$117.25M-$4.01-2.21 Is EPZM or BMEA more profitable? Biomea Fusion has a net margin of 0.00% compared to Epizyme's net margin of -391.90%. Biomea Fusion's return on equity of -118.90% beat Epizyme's return on equity.Company Net Margins Return on Equity Return on Assets Epizyme-391.90% -2,459.33% -69.74% Biomea Fusion N/A -118.90%-93.66% Do analysts prefer EPZM or BMEA? Biomea Fusion has a consensus price target of $30.50, indicating a potential upside of 243.47%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Epizyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Epizyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of EPZM or BMEA? 76.5% of Epizyme shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 23.4% of Epizyme shares are owned by insiders. Comparatively, 27.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, EPZM or BMEA? Epizyme has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Does the media prefer EPZM or BMEA? In the previous week, Biomea Fusion had 14 more articles in the media than Epizyme. MarketBeat recorded 14 mentions for Biomea Fusion and 0 mentions for Epizyme. Biomea Fusion's average media sentiment score of 0.36 beat Epizyme's score of 0.22 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Overall Sentiment Epizyme Neutral Biomea Fusion Neutral Does the MarketBeat Community prefer EPZM or BMEA? Epizyme received 427 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 65.79% of users gave Biomea Fusion an outperform vote while only 60.69% of users gave Epizyme an outperform vote. CompanyUnderperformOutperformEpizymeOutperform Votes47760.69% Underperform Votes30939.31% Biomea FusionOutperform Votes5065.79% Underperform Votes2634.21% SummaryBiomea Fusion beats Epizyme on 12 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$321.81M$6.95B$5.29B$8.82BDividend YieldN/A7.97%5.16%4.03%P/E Ratio-2.218.73116.1516.49Price / SalesN/A418.54671.85102.53Price / CashN/A22.5534.9631.66Price / Book1.875.514.714.66Net Income-$117.25M$154.22M$114.90M$224.13M7 Day Performance-14.12%0.31%2.07%2.20%1 Month Performance-15.27%16.28%7.99%6.23%1 Year Performance-4.10%41.91%38.33%32.04% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.8307 of 5 stars$8.88-0.3%$30.50+243.5%-11.7%$321.81MN/A-2.2150Analyst RevisionGap UpEPZMEpizymeN/A$1.47flatN/A+0.0%$247.44M$37.43M-0.85250CHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.3485ABOSAcumen Pharmaceuticals3.4011 of 5 stars$2.88-5.0%N/A+37.0%$182.04MN/A-2.5751Upcoming EarningsNews CoveragePRTKParatek PharmaceuticalsN/A$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268High Trading VolumeOVIDOvid Therapeutics4.2023 of 5 stars$1.13-1.7%N/A-65.0%$81.62M$390,000.00-2.6360Upcoming EarningsXNCRXencor4.004 of 5 stars$21.010.0%N/A+16.6%$1.47B$168.34M-7.27280News CoverageRCUSArcus Biosciences2.9147 of 5 stars$15.30-4.4%N/A-6.6%$1.46B$117M-4.95500Analyst ForecastNews CoverageGap UpNTLAIntellia Therapeutics4.4406 of 5 stars$14.22-0.8%N/A-46.3%$1.46B$36.28M-2.59600Upcoming EarningsGap UpEVOEvotec2.5583 of 5 stars$3.87-2.3%N/A-51.3%$1.40B$845.74M0.005,061News CoverageGap DownARDXArdelyx4.2472 of 5 stars$5.87-0.3%N/A+42.3%$1.39B$124.46M-21.74267Analyst ForecastInsider SellingAnalyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies EPZM Alternatives CHMA Alternatives ABOS Alternatives PRTK Alternatives OVID Alternatives XNCR Alternatives RCUS Alternatives NTLA Alternatives EVO Alternatives ARDX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMEA) was last updated on 11/6/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredURGENT: Dylan Jovine’s emergency briefingThe mainstream media tells you the US economy is doing great. But do you believe them? These are the sam...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.